Researchers from a Colorado University are using insulin to help identify those at risk of developing type 1 diabetes 24 February 2021 Researchers from the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus have found that immune responses to insulin could help identify individuals most at risk for developing type 1 diabetes. The study, out recently in the Proceedings of the National Academy of Sciences, measured immune responses from individuals genetically predisposed to developing type 1 diabetes to naturally occurring insulin and hybrid insulin peptides. Since not all genetically predisposed individuals develop type 1 diabetes, researchers sought to examine T-cell immune responses from the peripheral blood that could occur before the onset of clinical diabetes. “We want to know why people develop type 1 diabetes, and this research has helped provide a lot more information and data as to what it looks like when genetically at-risk individuals are headed towards clinical diagnosis,” says Aaron Michels, MD, the study’s lead researcher, Associate Professor of Medicine at CU Anschutz and researcher at the Barbara Davis Center. “Ideally, you want to treat a disease when it’s active, so this is a need in our field to understand when people have an immune response directed against insulin producing cells.” “We want to know why people develop type 1 diabetes, and this research has helped provide a lot more information and data as to what it looks like when genetically at-risk individuals are headed towards clinical diagnosis,” Researchers collected blood samples from genetically at-risk adolescents every 6 months for two years. Inflammatory T-cell responses to hybrid insulin peptides correlated with worsening blood glucose measurements and progression to type 1 diabetes development. The results indicate an important advancement in identifying the risk of type 1 diabetes early as well as the potential for intervention. “There are now therapies used in research studies that have delayed the onset of clinical type 1 diabetes,” says Michels. “Patients with these specific immune responses, may benefit from immune intervention to delay type 1 diabetes onset and possibly prevent it for years.” Furthermore, Michels says these results can lead to research beyond type 1 diabetes. “Our work focused on diabetes, but this has implications for other autoimmune diseases. Understanding how the immune system responds can be crucial in trying to prevent diseases before clinical symptoms are present.” https://news.cuanschutz.edu/news-stories/immune-response-to-insulin-could-identify-help-treat-those-at-risk-for-type-1-diabetes
Media releases 14 February 2025 Diabetes Australia thanks retiring Federal MPs for their dedication Diabetes Australia has this week extended its gratitude to retiring Federal MPs Graham Perrett and Rowan Ramsey for their tireless... Continue Reading
Media releases 13 February 2025 Diabetes Australia calls for election commitments to improve tech access Diabetes Australia representatives are in Federal Parliament this week calling on both sides of politics to commit to funding equitable... Continue Reading
News 4 February 2025 Urgent calls for diabetes funding in 2025-26 Federal Budget The Diabetes Alliance has called on the Federal Government to commit to, and fund, the recommendations of the Parliament Inquiry... Continue Reading